首页|血浆外泌体miR-3614表达量和MRI相关参数与宫颈癌同步放化疗后进展的相关性研究

血浆外泌体miR-3614表达量和MRI相关参数与宫颈癌同步放化疗后进展的相关性研究

扫码查看
目的 本研究主要探究血浆外泌体中微小RNA-3614(miR-3614)表达量和MRI相关参数与宫颈癌同步放化疗后进展的关系。方法 选取华北理工大学附属医院2020年3月-2023年2月的138例宫颈癌患者,于首次同步放化疗前用实时荧光定量PCR法检测血浆外泌体中miR-3614水平,并收集MRI参数。随访患者,分析宫颈癌同步放化疗后进展的风险因素。结果 患者中位年龄55(49,61)岁,国际妇产科联盟(FIGO)ⅡB期41例,Ⅲ期97例,中位随访时间为33(19,37)个月,41例(29。71%)同步放化疗后进展。COX回归(Forward:LR法)分析结果显示,校正FIGO分期、肿瘤直径、慢速表观弥散系数、容积转运常数和血管外细胞外间隙容积比后,淋巴结转移(HR=5。451,95%CI:2。691~11。043,P<0。001)和miR-3614>2。55(HR=4。168,95%CI:1。872~9。281,P<0。001)是同步放化疗后进展的独立危险因素,表观弥散系数(ADC)>0。52× 10 3mm2/s(HR=0。377,95%CI:0。172~0。826,P=0。015)和灌注相关体积分数(f)>0。23(HR=0。307,95%CI:0。124~0。763,P=0。011)是同步放化疗后进展的独立保护因素。结论 血浆外泌体中miR-3614、淋巴结转移、ADC和f均与宫颈癌同步放化疗后进展有关。
Correlation of plasma exosomal miR-3614 expression and MRI-related parameters with the progression of cervical cancer following concurrent chemoradiotherapy
Objective The benefit of concurrent chemoradiotherapy for cervical cancer patients varies widely,and there is a lack of clinical indicators to reflect the efficacy.This study aimed to investigate the relationship of plasma exosomal microRNA-3614(miR-3614)expression and MRI-related parameters with the progres-sion of cervical cancer following concurrent chemoradiotherapy.Methods A total of one hundred and thirty-eight cervical cancer patients admitted to the North China University of Science and Technology Affiliated Hospital between March 2020 and February 2023 were selected.Prior to the initial concurrent chemoradio-therapy,real-time fluorescence quantitative PCR was utilized to assess miR-3614 levels in plasma exosomes,while MRI parameters were recorded.Patients were followed up to identify risk factors for progression fol-lowing concurrent chemoradiotherapy for cervical cancer.Results The median age of the patients was 55(49,61)years.There were 41 patients with International Federation of Gynecology and Obstetrics(FIGO)StageⅡB and 97 patients with Stage Ⅲ.The median follow-up duration for all patients was 33(19,37)months,during which 41 cases(29.71%)experienced progression post concurrent chemoradiotherapy.COX regres-sion analysis employing the Forward:LR method revealed that,following adjustment for the FIGO stage,tumor diameter,slow apparent diffusion coefficient(ADC),volume transfer constant,and extravascular ex-tracellular volume ratio,lymph node metastasis(HR=5.451,95%CI:2.691~11.043,P<0.001)and miR-3614 levels exceeding 2.55(HR=4.168,95%CI:1.872~9.281,P<0.001)emerged as independent risk factors for progression post concurrent chemoradiotherapy.Conversely,ADC levels surpassing 0.52 X 10-3mm2/s(HR=0.377,95%CI:0.172~0.826,P=0.015)and perfusion-related volume fraction(f)excee-ding 0.23(HR=0.307,95%CI:0.124~0.763,P=0.011)were identified as independent protective factors.Conclusion The study findings suggest an association between plasma exosomal miR-3614,lymph node me-tastasis,ADC,and f with the progression of cervical cancer following concurrent chemoradiotherapy.

Cervical cancerConcurrent chemoradiotherapyExosomesmiR-3614MRI

王雅静、任俊杰、李伟兰、程慧欣、崔立强、谢宗源、郭艳娟、虞红

展开 >

063000 河北省唐山市,华北理工大学附属医院核磁室

河北省退役军人总医院CT/MR室

华北理工大学附属医院妇科

华北理工大学附属医院放疗科

展开 >

宫颈癌 同步放化疗 外泌体 miR-3614 MRI

河北省医学科学研究课题计划

20231255

2024

中国煤炭工业医学杂志
河北联合大学

中国煤炭工业医学杂志

CSTPCD
影响因子:0.692
ISSN:1007-9564
年,卷(期):2024.27(4)